@article {969,
	title = {Short and long-term safety of lenograstim administration in healthy peripheral haematopoietic progenitor cell donors: a single centre experience},
	journal = {Bone Marrow Transplantation},
	volume = {44},
	year = {2009},
	note = {HPC Martino M Console G Dattola A Callea I Messina G Moscato T Massara E Irrera G Fedele R Gervasi A Bresolin G Iacopino P Journal Article},
	month = {Aug},
	pages = {163 - 8},
	abstract = {Healthy donors (HDs) who were mobilized using lenograstim (LENO) and who were undergoing peripheral haematopoietic progenitor cell collection with apheresis (HPC-A) were enrolled in a surveillance protocol. In all, 184 HDs have been assessed with a median follow-up of 62 months (range 2-155). HDs received LENO at a median dose of 10 microg/kg (range 5-15). Bone pain was reported as the most frequent short-term adverse event (71.2\%). Other commonly observed short-term symptoms included fatigue (19.0\%), fever (5.4\%), headache (27.7\%), nausea (12.0\%) and insomnia (22.3\%). Spleen size increased in 4.3\% of the donors. No vascular disorders or cardiac disease occurred. Long-term follow-up included monitoring of adverse events, neoplastic disease or other pathologies. Transit ischaemic attack occurred in one donor (39 months post-donation). One autoimmune event was reported at 28 months post-recombinant human granulocyte (rhG)-CSF (ankylosing spondylitis); one donor with a history of chronic obstructive pulmonary disease developed secondary polyglobulia (50 months post-rhG-CSF). One donor was diagnosed with lung cancer at 19 months post-donation. No haematological disease was observed. In conclusion, the short-term safety appears to be verified, whereas, although the study identified no increased risks of malignancy among HDs who received rhG-CSF, long-term safety requires more complete data sets, especially a longer follow-up and a larger number of HDs.},
	author = {Martino,M. and Console,G. and Dattola,A. and Callea,I. and Messina,G. and Moscato,T. and Massara,E. and Irrera,G. and Fedele,R. and Gervasi,A. and Bresolin,G. and Iacopino,P.}
}
